This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
This version underwent another three weeks of testing to become the final release code; the game was still unfinished when Activision forced its release. Bloodlines' creative director Jason Anderson blamed Activision, saying that the publisher took the game from Troika without providing enough time to test and polish it. Conversely, Boyarsky defended Activision for supporting Troika as the project exceeded its budget and schedule. During the nearly four years of development, Anderson estimated that the team worked overtime for all but two months.
=== Legal status === In June 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Onswik, intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Eli Lilly Nederland. Insulin efsitora alfa was authorized for medical use in the European Union in August 2026. Insulin efsitora alfa was approved for medical use in the United States in September 2026.
=== Controversy === In 2015, ex-Transportation corps commander Major General Liu Zhanqi, ex-Transportation corps Political commissar Major General Wang Xin and ex-Transportation Corps Chief engineer Major General Miao Guirong were arrested on 16 June, 31 July and 15 September respectively on corruption-related charges as part of the anti-corruption campaign under Xi Jinping. As of 16 September 2015, a total of 43 people were arrested in relation to the case.
Laboratory equipment refers to the various tools and equipment used by scientists working in a laboratory. Laboratory equipment is generally used to either perform an experiment or to take measurements and gather data. Larger or more sophisticated equipment is generally called a scientific instrument. The classical equipment includes tools such as Bunsen burners and microscopes as well as specialty equipment such as operant conditioning chambers, bioreactors, hematology analyzers, autoclaves, centrifuges, spectrophotometers and calorimeters, glucometer, incubator.
== Method == Generally, negative ions are created (atoms are ionized) in an ion source. In fortunate cases, this already allows the suppression of an unwanted isobar, which does not form negative ions (as 14N in the case of 14C measurements). The pre-accelerated ions are usually separated by a first mass spectrometer of sector-field type and enter an electrostatic "tandem accelerator". This is a large nuclear particle accelerator based on the principle of a tandem van de Graaff accelerator operating at 0.2 to many million volts with two stages operating in tandem to accelerate the particles. At the connecting point between the two stages, the ions change charge from negative to positive by passing through a thin layer of matter ("stripping", either gas or a thin carbon foil). Molecules will break apart in this stripping stage. The complete suppression of molecular isobars (e.g. 13CH− in the case of 14C measurements) is one reason for the exceptional abundance sensitivity of AMS. Additionally, the impact strips off several of the ion's electrons, converting it into a positively charged ion. In the second half of the accelerator, the now positively charged ion is accelerated away from the highly positive centre of the electrostatic accelerator which previously attracted the negative ion. When the ions leave the accelerator they are positively charged and are moving at several percent of the speed of light. In the second stage of mass spectrometer, the fragments from the molecules are separated from the ions of interest.
Sources: en.wikipedia.org
== History == RO5203648 was first described by 2012. It was the first selective TAAR1 partial agonist to be developed. The drug followed the first TAAR1 antagonist EPPTB and the first TAAR1 full agonist RO5166017. It was under investigation for potential clinical use in humans, but showed indication of very rapid human metabolism in vitro. As a result, it was deselected from development, and other compounds, such as the TAAR1 partial agonist RO5263397, were pursued instead.
Eating much faster than normal, perhaps in a short space of time Eating until feeling uncomfortably full Eating a large amount even when not hungry Subjective loss of control over how much or what is eaten Planning and allocating specific times for bingeing Eating alone or secretly Not being able to remember what was eaten after the binge Feelings of guilt, shame, or disgust following a food binge Body image disturbance In contrast to bulimia nervosa, binge eating episodes are not regularly followed by activities intended to compensate for the amount of food consumed, such as self-induced vomiting, laxative or enema misuse, or strenuous exercise. BED is characterized more by overeating than dietary restriction. Those with BED often have poor body image and frequently diet, but are unsuccessful due to the severity of their binge eating. Obesity is common in persons with BED, as are depression, low self-esteem, stress and boredom. Regarding cognitive abilities, individuals showing severe binge eating symptoms may experience small dysfunctions in executive functions. Those with BED are also at risk of non-alcoholic fatty liver disease, menstrual irregularities such as amenorrhea, and gastrointestinal problems such as acid reflux and heartburn.
Two years earlier, she had developed a new process of using potatoes to make flour and alcohol, which subsequently lessened Sweden's reliance on wheat crops and decreased the risk of famine. 1751: 19-year-old Italian physicist Cristina Roccati received her PhD from the University of Bologna. 1753: American botanist Jane Colden was the only female biologist mentioned by Carl Linnaeus in his masterwork Species Plantarum. 1754: German physician Dorothea Erxleben was the first female to be awarded a doctor in medicine in Germany (University of Halle, then Kingdom of Prussia). She practiced medicine from 1747 to 1762 in Quedlinburg. 1755: After the death of her husband, Italian anatomist Anna Morandi Manzolini took his place at the University of Bologna, becoming a professor of anatomy and establishing an internationally known laboratory for anatomical research. 1757: French astronomer Nicole-Reine Lepaute worked with mathematicians Alexis Clairaut and Joseph Lalande to calculate the next arrival of Halley's Comet. 1760: American horticulturalist Martha Daniell Logan began corresponding with botanic specialist and collector John Bartram, regularly exchanging seeds, plants and botanical knowledge with him. 1762: French astronomer Nicole-Reine Lepaute calculated the time and percentage of a solar eclipse that had been predicted to occur in two years time. She created a map to show the phases, and published a table of her calculations in the 1763 edition of Connaissance des Temps. 1766: French chemist Geneviève Thiroux d'Arconville published her study on putrefaction.
EC 1.14.14.5: alkanesulfonate monooxygenase EC 1.14.14.6: Now EC 1.14.13.111, methanesulfonate monooxygenase EC 1.14.14.7: transferred to EC 1.14.19.9, tryptophan 7-halogenase EC 1.14.14.8: anthranilate 3-monooxygenase (FAD) EC 1.14.14.9: 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.14.10: nitrilotriacetate monooxygenase EC 1.14.14.11: styrene monooxygenase EC 1.14.14.12: 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione monooxygenase EC 1.14.14.13: 4-(γ-L-glutamylamino)butanoyl-[BtrI acyl-carrier protein] monooxygenase EC 1.14.14.14: aromatase EC 1.14.14.15: (3S)-3-amino-3-(3-chloro-4-hydroxyphenyl)propanoyl-[peptidyl-carrier protein SgcC2] monooxygenase EC 1.14.14.16: steroid 21-monooxygenase EC 1.14.14.17: squalene monooxygenase EC 1.14.14.18: heme oxygenase (biliverdin-producing) EC 1.14.14.19: steroid 17α-monooxygenase EC 1.14.14.20: phenol 2-monooxygenase (FADH2) EC 1.14.14.21: dibenzothiophene monooxygenase EC 1.14.14.22: dibenzothiophene sulfone monooxygenase EC 1.14.14.23: cholesterol 7α-monooxygenase EC 1.14.14.24: vitamin D 25-hydroxylase EC 1.14.14.25: cholesterol 24-hydroxylase EC 1.14.14.26: 24-hydroxycholesterol 7α-hydroxylase EC 1.14.14.27: resorcinol 4-hydroxylase (FADH2) EC 1.14.14.28: long-chain alkane monooxygenase EC 1.14.14.29: 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.14.30: isobutylamine N-monooxygenase EC 1.14.14.31: ipsdienol synthase EC 1.14.14.32: 17α-hydroxyprogesterone deacetylase EC 1.14.14.33: ethylenediaminetetraacetate monooxygenase EC 1.14.14.34: methanesulfonate monooxygenase (FMNH2) EC 1.14.14.35: dimethylsulfone monooxygenase EC 1.14.14.36: tyrosine N-monooxygenase EC 1.14.14.37: 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.14.38: valine N-monooxygenase EC 1.14.14.39: isoleucine N-monooxygenase EC 1.14.14.40: phenylalanine N-monooxygenase EC 1.14.14.41: (E)-2-methylbutanal oxime monooxygenase EC 1.14.14.42: homomethionine N-monooxygenase EC 1.14.14.43: (methylsulfanyl)alkanaldoxime N-monooxygenase EC 1.14.14.44: phenylacetaldehyde oxime monooxygenase EC 1.14.14.45: aromatic aldoxime N-monooxygenase EC 1.14.14.46: pimeloyl-[acyl-carrier protein] synthase EC 1.14.14.47: nitric-oxide synthase (flavodoxin) EC 1.14.14.48: jasmonoyl-L-amino acid 12-hydroxylase EC 1.14.14.49: 12-hydroxyjasmonoyl-L-amino acid 12-hydroxylase EC 1.14.14.50: tabersonine 3-oxygenase EC 1.14.14.51: (S)-limonene 6-monooxygenase EC 1.14.14.52: (S)-limonene 7-monooxygenase EC 1.14.14.53: (R)-limonene 6-monooxygenase EC 1.14.14.54: phenylacetate 2-hydroxylase EC 1.14.14.55: quinine 3-monooxygenase EC 1.14.14.56: 1,8-cineole 2-exo-monooxygenase EC 1.14.14.57: taurochenodeoxycholate 6α-hydroxylase EC 1.14.14.58: trimethyltridecatetraene synthase EC 1.14.14.59: dimethylnonatriene synthase EC 1.14.14.60: ferruginol monooxygenase EC 1.14.14.61: carnosic acid synthase EC 1.14.14.62: salviol synthase EC 1.14.14.63: β-amyrin 16β-monooxygenase EC 1.14.14.64: β-amyrin 6β-monooxygenase EC 1.14.14.65: sugiol synthase EC 1.14.14.66: marmesin synthase EC 1.14.14.67: 11-hydroxysugiol 20-monooxygenase EC 1.14.14.68: syn-pimaradiene 3-monooxygenase EC 1.14.14.69: ent-cassadiene hydroxylase EC 1.14.14.70: ent-sandaracopimaradiene 3-hydroxylase EC 1.14.14.71: cucurbitadienol 11-hydroxylase EC 1.14.14.72: drimenol monooxygenase EC 1.14.14.73: albendazole monooxygenase (sulfoxide-forming) EC 1.14.14.74: albendazole monooxygenase (hydroxylating) EC 1.14.14.75: fenbendazole monooxygenase (4′-hydroxylating) EC 1.14.14.76: ent-isokaurene C2/C3-hydroxylase EC 1.14.14.77: phenylacetonitrile α-monooxygenase EC 1.14.14.78: phylloquinone ω-hydroxylase EC 1.14.14.79: docosahexaenoic acid ω-hydroxylase EC 1.14.14.80: long-chain fatty acid ω-monooxygenase EC 1.14.14.81: flavanoid 3′,5′-hydroxylase EC 1.14.14.82: flavonoid 3′-monooxygenase EC 1.14.14.83: geraniol 8-hydroxylase EC 1.14.14.84: linalool 8-monooxygenase EC 1.14.14.85: 7-deoxyloganate 7-hydroxylase EC 1.14.14.86: ent-kaurene monooxygenase EC 1.14.14.87: 2-hydroxyisoflavanone synthase EC 1.14.14.88: isoflavone 3′-hydroxylase EC 1.14.14.89: 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.14.90: isoflavone 2′-hydroxylase EC 1.14.14.91: trans-cinnamate 4-monooxygenase EC 1.14.14.92: benzoate 4-monooxygenase EC 1.14.14.93: 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.14.94: leukotriene-B4 20-monooxygenase EC 1.14.14.95: germacrene A hydroxylase EC 1.14.14.96: 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.14.97: methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.14.98: protopine 6-monooxygenase EC 1.14.14.99: (S)-limonene 3-monooxygenase EC 1.14.14.100: dihydrosanguinarine 10-monooxygenase EC 1.14.14.101: dihydrochelirubine 12-monooxygenase EC 1.14.14.102: N-methylcoclaurine 3′-monooxygenase EC 1.14.14.103: tabersonine 16-hydroxylase EC 1.14.14.104: vinorine hydroxylase EC 1.14.14.105: taxane 10β-hydroxylase EC 1.14.14.106: taxane 13α-hydroxylase EC 1.14.14.107: ent-kaurenoic acid monooxygenase EC 1.14.14.108: 2,5-diketocamphane 1,2-monooxygenase EC 1.14.14.109: 3-hydroxyindolin-2-one monooxygenase EC 1.14.14.110: 2-hydroxy-1,4-benzoxazin-3-one monooxygenase EC 1.14.14.111: 9β-pimara-7,15-diene oxidase EC 1.14.14.112: ent-cassa-12,15-diene 11-hydroxylase EC 1.14.14.113: α-humulene 10-hydroxylase EC 1.14.14.114: amorpha-4,11-diene 12-monooxygenase EC 1.14.14.115: 11-oxo-β-amyrin 30-oxidase EC 1.14.14.116: averantin hydroxylase EC 1.14.14.117: aflatoxin B synthase EC 1.14.14.118: tryprostatin B 6-hydroxylase EC 1.14.14.119: fumitremorgin C monooxygenase EC 1.14.14.120: dammarenediol 12-hydroxylase EC 1.14.14.121: protopanaxadiol 6-hydroxylase EC 1.14.14.122: oryzalexin E synthase EC 1.14.14.123: oryzalexin D synthase EC 1.14.14.124: dihydromonacolin L hydroxylase EC 1.14.14.125: monacolin L hydroxylase EC 1.14.14.126: β-amyrin 28-monooxygenase EC 1.14.14.127: methyl farnesoate epoxidase EC 1.14.14.128: farnesoate epoxidase EC 1.14.14.129: long-chain acyl-CoA ω-monooxygenase EC 1.14.14.130: laurate 7-monooxygenase EC 1.14.14.131: bursehernin 5′-monooxygenase EC 1.14.14.132: (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.14.133: 1,8-cineole 2-endo-monooxygenase EC 1.14.14.134: β-amyrin 24-hydroxylase EC 1.14.14.135: glyceollin synthase EC 1.14.14.136: deoxysarpagine hydroxylase EC 1.14.14.137: (+)-abscisic acid 8′-hydroxylase EC 1.14.14.138: lithocholate 6β-hydroxylase EC 1.14.14.139: 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.14.140: Now included with EC 1.14.14.162 EC 1.14.14.162, flavanone 2-hydroxylase EC 1.14.14.141: psoralen synthase EC 1.14.14.142: 8-dimethylallylnaringenin 2′-hydroxylase EC 1.14.14.143: (+)-menthofuran synthase EC 1.14.14.144: abieta-7,13-diene hydroxylase EC 1.14.14.145: abieta-7,13-dien-18-ol hydroxylase EC 1.14.14.146: geranylgeraniol 18-hydroxylase EC 1.14.14.147: 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.14.148: angelicin synthase EC 1.14.14.149: 5-epiaristolochene 1,3-dihydroxylase EC 1.14.14.150: costunolide synthase EC 1.14.14.151: premnaspirodiene oxygenase EC 1.14.14.152: β-amyrin 11-oxidase EC 1.14.14.153: indole-2-monooxygenase EC 1.14.14.154: sterol 14α-demethylase EC 1.14.14.155: 3,6-diketocamphane 1,2-monooxygenase EC 1.14.14.156: tryptophan N-monooxygenase EC 1.14.14.157: indolin-2-one monooxygenase EC 1.14.14.158: carotenoid ε hydroxylase EC 1.14.14.159: dolabradiene monooxygenase EC 1.14.14.160: zealexin A1 synthase EC 1.14.14.161: nepetalactol monooxygenase EC 1.14.14.162: flavanone 2-hydroxylase EC 1.14.14.163: (S)-1-hydroxy-N-methylcanadine 13-hydroxylase EC 1.14.14.164: fraxetin 5-hydroxylase EC 1.14.14.165: indole-3-carbonyl nitrile 4-hydroxylase EC 1.14.14.166: (S)-N-methylcanadine 1-hydroxylase EC 1.14.14.167: (13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine 8-hydroxylase EC 1.14.14.168: germacrene A acid 8β-hydroxylase EC 1.14.14.169: eupatolide synthase EC 1.14.14.170: 8-epi-inunolide synthase EC 1.14.14.171: β-amyrin 16α-hydroxylase EC 1.14.14.172: 3,5,6-trichloropyridin-2-ol monooxygenase EC 1.14.14.173: 2,4,6-trichlorophenol monooxygenase EC 1.14.14.174: geranylhydroquinone 3′′-hydroxylase EC 1.14.14.175: ferruginol synthase EC 1.14.14.176: taxadiene 5α-hydroxylase EC 1.14.14.177: ultra-long-chain fatty acid ω-hydroxylase EC 1.14.14.182: taxoid 7beta-hydroxylase EC 1.14.14.197: progesterone 11alpha-monooxygenase
== Treatment == Treatment for neurofibrosarcoma is similar to that of other cancers. Surgery is an option; the removal of the tumor along with surrounding tissue may be vital for the patient's survival. For discrete, localized tumors, surgery is often followed by radiation therapy of the excised area to reduce the chance of recurrence. For patients who have neurofibrosarcomas in an extremity, if the tumor is vascularized (has its own blood supply) and has many nerves going through it and/or around it, amputation of the extremity may be necessary. Some surgeons argue that amputation should be the procedure of choice when possible, due to the increased chance of a better quality of life. Otherwise, surgeons may opt for a limb-saving treatment, by removing less of the surrounding tissue or part of the bone, which is replaced by a metal rod or grafts. Radiation will also be used in conjunction with surgery, especially if the limb was not amputated. Radiation is rarely used as a sole treatment. In some instances, the oncologist may choose chemotherapy drugs when treating a patient with neurofibrosarcoma, usually in conjunction with surgery. Patients taking chemotherapy must be prepared for the side effects that come with any other chemotherapy treatment, such as; hair loss, lethargy, weakness, etc.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.